Dhruvitkumar S Sutaria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1508865/publications.pdf

Version: 2024-02-01

24 papers 917 citations

777949 13 h-index 799663 21 g-index

24 all docs

24 docs citations

times ranked

24

1885 citing authors

#	Article	IF	CITATIONS
1	Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. Journal of Extracellular Vesicles, 2017, 6, 1324730.	5.5	357
2	Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading. Pharmaceutical Research, 2017, 34, 1053-1066.	1.7	94
3	Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen. International Journal of Oncology, 2012, 41, 2260-2268.	1.4	65
4	Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery. Journal of Extracellular Vesicles, 2017, 6, 1333882.	5.5	65
5	First Penicillin-Binding Protein Occupancy Patterns of \hat{l}^2 -Lactams and \hat{l}^2 -Lactamase Inhibitors in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	48
6	The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer. Oncology Reports, 2013, 29, 1671-1677.	1.2	39
7	Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. Oncotarget, 2016, 7, 53165-53177.	0.8	37
8	miR-216 and miR-217 expression is reduced in transgenic mouse models of pancreatic adenocarcinoma, knockout of miR-216/miR-217 host gene is embryonic lethal. Functional and Integrative Genomics, 2017, 17, 203-212.	1.4	27
9	CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget, 2018, 9, 26032-26045.	0.8	26
10	Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	24
11	Chemoprevention of Colon Cancer in a Rat Carcinogenesis Model Using a Novel Nanotechnology-Based Combined Treatment System. Cancer Prevention Research, 2011, 4, 1655-1664.	0.7	23
12	Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma. Non-coding RNA, 2017, 3, 24.	1.3	19
13	Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five \hat{l}^2 -Lactams Simultaneously in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i> MBio, 2020, 11, .	1.8	17
14	First Penicillin-Binding Protein Occupancy Patterns for 15 \hat{l}^2 -Lactams and \hat{l}^2 -Lactamase Inhibitors in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	16
15	Knockout of Acinar Enriched microRNAs in Mice Promote Duct Formation But Not Pancreatic Cancer. Scientific Reports, 2019, 9, 11147.	1.6	14
16	Loss of RE-1 silencing transcription factor accelerates exocrine damage from pancreatic injury. Cell Death and Disease, 2020, 11, 138.	2.7	12
17	Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. Pharmaceutics, 2019, 11, 286.	2.0	10
18	Combating Multidrugâ€Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. Clinical Pharmacology and Therapeutics, 2021, 109, 1000-1020.	2.3	10

#	Article	IF	CITATIONS
19	First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. European Journal of Pharmaceutical Sciences, 2018, 123, 416-428.	1.9	6
20	Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics. Pharmaceutics, 2019, 11, 323.	2.0	4
21	Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function. Journal of Clinical Pharmacology, 2022, 62, 171-181.	1.0	3
22	Abstract 2068: Engineering of hairpin loop enhances the loading of endogenously expressed pre-miRNA into extracellular vesicles. , 2016 , , .		1
23	Abstract 4591: Comparison of the inhibitory effects of unmodified and modified combinations of chemopreventive agents on MIA PaCa-2 and Panc-1 human pancreatic cancer cell lines., 2011,,.		О
24	Abstract 141: CD44 positive and sorafenib resistant hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. , 2017, , .		0